1. Home
  2. VMD vs NMRA Comparison

VMD vs NMRA Comparison

Compare VMD & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VMD
  • NMRA
  • Stock Information
  • Founded
  • VMD 2006
  • NMRA 2019
  • Country
  • VMD United States
  • NMRA United States
  • Employees
  • VMD N/A
  • NMRA N/A
  • Industry
  • VMD
  • NMRA
  • Sector
  • VMD
  • NMRA
  • Exchange
  • VMD Nasdaq
  • NMRA Nasdaq
  • Market Cap
  • VMD N/A
  • NMRA 287.6M
  • IPO Year
  • VMD N/A
  • NMRA 2023
  • Fundamental
  • Price
  • VMD $7.39
  • NMRA $1.01
  • Analyst Decision
  • VMD
  • NMRA Buy
  • Analyst Count
  • VMD 0
  • NMRA 8
  • Target Price
  • VMD N/A
  • NMRA $10.14
  • AVG Volume (30 Days)
  • VMD 112.5K
  • NMRA 1.2M
  • Earning Date
  • VMD 03-10-2025
  • NMRA 03-03-2025
  • Dividend Yield
  • VMD N/A
  • NMRA N/A
  • EPS Growth
  • VMD 12.00
  • NMRA N/A
  • EPS
  • VMD 0.28
  • NMRA N/A
  • Revenue
  • VMD $224,257,000.00
  • NMRA N/A
  • Revenue This Year
  • VMD $13.27
  • NMRA N/A
  • Revenue Next Year
  • VMD $14.11
  • NMRA N/A
  • P/E Ratio
  • VMD $26.39
  • NMRA N/A
  • Revenue Growth
  • VMD 22.54
  • NMRA N/A
  • 52 Week Low
  • VMD $6.21
  • NMRA $0.95
  • 52 Week High
  • VMD $9.81
  • NMRA $17.19
  • Technical
  • Relative Strength Index (RSI)
  • VMD 45.02
  • NMRA 26.42
  • Support Level
  • VMD $7.12
  • NMRA $1.12
  • Resistance Level
  • VMD $7.30
  • NMRA $1.23
  • Average True Range (ATR)
  • VMD 0.22
  • NMRA 0.10
  • MACD
  • VMD 0.00
  • NMRA 0.04
  • Stochastic Oscillator
  • VMD 32.94
  • NMRA 2.18

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Share on Social Networks: